BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026 in New York. The X4 team will hold a fireside chat on February 12th at 12:30 p.m. ET and will be available for one-on-one meetings with investors. A webcast of the fireside chat will be available under the “Events ...

Core Viewpoint - X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. Company Performance and Outlook - The recent upgrade for X4 Pharmaceuticals reflects an improvement in its underlying business, suggesting that investors may respond positively by driving the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for X4 Pharmaceuticals has increased by 54.4%, indicating a strong upward trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of generating significant returns, particularly for Zacks Rank 1 stocks [7]. - X4 Pharmaceuticals' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by approximately 200 points on Wednesday [1] Group 2: Dynavax Technologies Corp - Shares of Dynavax Technologies Corp rose significantly after Sanofi SA announced its acquisition for $15.50 per share in cash, totaling an equity value of around $2.2 billion [1] - The acquisition enhances Sanofi's position in the adult immunization market [1] - Dynavax shares surged by 38.6% to close at $15.44 on Wednesday [1] Group 3: Other Notable Stock Movements - Omeros Corp shares increased by 66.8% to $14.60 following FDA approval of YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy [3] - Edgewise Therapeutics Inc gained 23.8% to $26.94 after updates from the ongoing CIRRUS-HCM Phase 2 trial of EDG-7500 [3] - Agios Pharmaceuticals Inc shares surged by 17.9% to $29.00 after FDA approval of AQVESME for treating anemia in adults with thalassemia, priced at approximately $425,000 per patient per year [3] - Wheels Up Experience Inc saw a gain of 14.8% to $0.73 [3] - Travere Therapeutics Inc increased by 14.3% to $40.41 [3] - Coincheck Group NV shares rose by 12.5% to $2.88 [3] - Polestar Automotive Holding UK Plc jumped 11.8% to $16.92 after announcing a $300 million equity investment [3] - CapsoVision Inc gained 11.6% to $14.39 [3] - X4 Pharmaceuticals Inc increased by 9.5% to $4.52 [3] - Falcon's Beyond Global Inc shares rose by 9.4% to $18.35 following a $100 million mixed shelf offering [3] - BIOAGE Labs Inc jumped 8.8% to $14.37 [3] - Kodiak Sciences Inc gained 8.6% to $29.81 [3] - UiPath Inc increased by 7.9% to $17.23 after being announced as a replacement for Synovus Financial in the S&P MidCap 400 [3] - Immuneering Corp rose by 6.8% to $6.83, with an upcoming update on a clinical trial scheduled for January 7, 2026 [3] - Nike Inc shares gained 4.7% to $60.03 amid mixed investor sentiment regarding insider purchases and concerns over tariffs and demand in China [3] - Micron Technology Inc increased by 3.5% to $286.01 [3]

Group 1 - X4 Pharmaceuticals, Inc. (XFOR) has reached a key level of support, indicating a potential bullish breakout as its 50-day simple moving average has crossed above its 200-day simple moving average, forming a "golden cross" [1] - A golden cross signifies a trend reversal, starting from a downtrend, followed by the shorter moving average crossing above the longer moving average, and culminating in an upward price movement [2] - XFOR shares have increased by 8.4% over the past four weeks, and the company holds a 3 (Hold) rating on the Zacks Rank, suggesting a potential for further gains [3] Group 2 - There have been four upward revisions in earnings expectations for XFOR in the current quarter, with no downward revisions, indicating a positive sentiment among investors [3] - The Zacks Consensus Estimate for XFOR has also moved up, reinforcing the bullish outlook for the company [5]

Core Insights - X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on its primary asset, Mavorixafor, which is commercially branded as Xolremdi and approved in the US for WHIM syndrome [1] Company Overview - The company is in the process of expanding the use of Mavorixafor beyond its current approval for WHIM syndrome [1]

Core Insights - X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on its primary asset, Mavorixafor, which is commercially branded as Xolremdi and approved in the US for WHIM syndrome [1] Group 1 - The treatment Xolremdi is currently in the process of expanding its indications beyond WHIM syndrome [1]

Summary of X4 Pharmaceuticals FY Conference Call Company Overview - **Company**: X4 Pharmaceuticals (NasdaqCM:XFOR) - **Focus**: Specializes in rare hematology diseases, particularly chronic neutropenia and WHIM syndrome [4][5] Key Points Management Transition - New management team joined X4 Pharmaceuticals three months prior, focusing on restructuring and financing [2] - Raised nearly $240 million to fund the phase 3 trial for chronic neutropenia [2] Lead Compound: Mavorixafor - **Indications**: Approved for WHIM syndrome, now targeting chronic neutropenia [9] - **Mechanism of Action**: Antagonizes CXCR4, facilitating the release of neutrophils from bone marrow into the bloodstream [7] - **Administration**: Oral agent, providing a competitive advantage over G-CSF, which requires injections and can cause discomfort [8] Market Opportunity - Estimated patient population for chronic neutropenia is approximately 15,000, significantly larger than the WHIM indication [5][12] - Current management of chronic neutropenia is inconsistent, with 40-45% of patients receiving G-CSF and 60% managed through other means [10][11] Clinical Trials - **Phase 2 Study**: Demonstrated that mavorixafor can increase ANC levels and can be safely combined with G-CSF [13][14] - **Phase 3 Study**: Double-blinded, placebo-controlled trial with 176 patients, focusing on ANC increase and reduction in infection rates [17][20] - Expected to complete enrollment by Q3 2026, with top-line data anticipated in the second half of 2027 [25] Competitive Landscape - Main competitor is G-CSF; no direct oral competitors currently exist [28] - Focus on generating combination data with G-CSF in the ongoing study [28] Commercialization Strategy - Plans to target a similar prescriber base as previous experiences with CTI and Bendeka [27] - Anticipates a premium pricing environment typical for rare diseases, though specific pricing strategies are still under development [27] Future Milestones - Completion of patient enrollment in the phase 3 trial is a critical upcoming milestone [29] - Ongoing efforts to better communicate market opportunities to investors [29] Collaborations - Strong relationship with Norjin for European rights, while focusing on the US market for commercialization [31] Additional Insights - The WHIM data collected from previous trials is being used to inform assumptions for the larger chronic neutropenia trial [9] - The company is restructuring to enhance trial enrollment efforts, particularly in the US [23][24]

Core Insights - X4 Pharmaceuticals will participate in the Guggenheim Second Annual Healthcare Innovation Conference from November 10-12, 2025, in Boston [1] - The management team will hold a fireside chat on November 10th at 8:30 a.m. ET and will be available for one-on-one meetings with investors [1] - A webcast of the fireside chat will be available on the company's website, with a replay accessible for 30 days post-event [2] Company Overview - X4 Pharmaceuticals focuses on developing and commercializing innovative therapies for patients with rare hematology diseases and significant unmet needs [3] - The company has developed mavorixafor, an orally available CXCR4 antagonist, currently marketed in the U.S. as XOLREMDI for its first indication [3] - X4 is conducting a global pivotal Phase 3 clinical trial (4WARD) for mavorixafor in patients with certain chronic neutropenic disorders [3]

Core Insights - X4 Pharmaceuticals reported a quarterly loss of $0.69 per share, better than the Zacks Consensus Estimate of a loss of $0.79, and a significant improvement from a loss of $5.41 per share a year ago, resulting in an earnings surprise of +12.66% [1] - The company generated revenues of $1.77 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 7.2%, but showing growth from $0.56 million in the same quarter last year [2] - X4 Pharmaceuticals shares have declined approximately 82% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for X4 Pharmaceuticals was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] - Current consensus EPS estimate for the next quarter is -$0.44 on revenues of $2.1 million, and for the current fiscal year, it is -$3.40 on revenues of $34.81 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which X4 Pharmaceuticals belongs, is currently ranked in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alvotech, another company in the same industry, is expected to report quarterly earnings of $0.05 per share, reflecting a year-over-year decline of 73.7%, with revenues projected at $128.22 million, up 24.5% from the previous year [9]

Financial Performance - Total revenue for Q3 2025 was $1.765 million, a significant increase from $560,000 in Q3 2024, representing a growth of 215% year-over-year[14] - Product revenue for the nine months ended September 30, 2025, reached $4.252 million, compared to $1.123 million for the same period in 2024, marking an increase of 278%[14] - For the nine months ended September 30, 2025, total revenue was $32.5 million, significantly up from $1.1 million in the same period of 2024, indicating a 2,841% increase[141] - The company reported net product revenue of $1.6 million for the three months ended September 30, 2025, an increase from $0.6 million in the same period of 2024, and total net revenue of $4.3 million for the nine months ended September 30, 2025, compared to $1.1 million for the same period in 2024[82] - For the three months ended September 30, 2025, the company recognized $1.8 million in revenue from external customers, compared to $0.6 million for the same period in 2024, representing a 196% increase[140] Net Loss and Expenses - The company reported a net loss of $29.815 million for Q3 2025, compared to a net loss of $36.696 million in Q3 2024, indicating an improvement of 18%[14] - For the nine months ended September 30, 2025, the company reported a net loss of $55.3 million, compared to a net income of $2.4 million for the same period in 2024[25] - The net loss for the three months ended September 30, 2025, was $29.8 million, compared to a net loss of $36.7 million for the same period in 2024, indicating an improvement of 18.9%[14] - Direct research and development expenses for the three months ended September 30, 2025, were $10.3 million, compared to $9.7 million in the same period of 2024, showing an increase of 6.4%[141] - Research and development expenses for Q3 2025 were $17.337 million, a decrease of 10% from $19.173 million in Q3 2024[14] Cash and Liquidity - Cash and cash equivalents increased to $69.632 million as of September 30, 2025, up from $55.699 million at the end of 2024, reflecting a growth of 25%[11] - As of September 30, 2025, total cash, cash equivalents, and restricted cash amounted to $70,435 thousand, an increase from $56,475 thousand as of December 31, 2024, representing a 24.5% increase[55] - The company reported a net cash used in operating activities of $70,091,000 for the nine months ended September 30, 2025, compared to $97,906,000 for the same period in 2024[25] - The company believes its current cash and cash equivalents will be sufficient to fund operations for at least the next 12 months[40] - As of September 30, 2025, the company had $122.2 million in cash, cash equivalents, and short-term marketable securities, with an accumulated deficit of $570.6 million[37] Assets and Liabilities - Total assets as of September 30, 2025, were $163.555 million, an increase of 12% from $146.447 million at the end of 2024[11] - Total liabilities decreased to $101.936 million as of September 30, 2025, down from $124.298 million at the end of 2024, representing a reduction of 18%[11] - The company’s accumulated deficit increased to $570.629 million as of September 30, 2025, compared to $515.355 million at the end of 2024[11] - The total stockholders' equity rose to $61.6 million as of September 30, 2025, compared to $22.1 million as of December 31, 2024, representing a substantial increase of 178.3%[11] Stock and Shareholder Information - The weighted average shares outstanding for basic net loss per share increased to 43,272,773 in Q3 2025, compared to 6,695,509 in Q3 2024[14] - The company executed a 1-for-30 reverse stock split on April 28, 2025, affecting all common stock share amounts retroactively[8] - The company excluded 15,633 potential shares of common stock from the computation of diluted net loss per share for the three months ended September 30, 2025, due to their anti-dilutive effect[70] - The company’s weighted average shares of common stock outstanding for the three months ended September 30, 2025, were 43,272,773 for both basic and diluted calculations[67] Clinical Development and Regulatory Status - The company is progressing in its pivotal Phase 3 clinical trial (the "4WARD" trial) for mavorixafor, with full enrollment expected in Q3 2026[28] - The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, a rare blood condition[28] - The company has one commercially approved product, XOLREMDI® (mavorixafor), for patients with WHIM syndrome[28] Strategic Restructuring - The company implemented a strategic restructuring in Q1 2025, resulting in a 30% reduction of its workforce, incurring charges of approximately $2.3 million for severance and related costs[74] - An additional strategic restructuring was announced on September 17, 2025, leading to a further workforce reduction of approximately 50%, with expenses of about $4.9 million for severance and related costs[75] Agreements and Contracts - The Company has entered into a license and supply agreement with Norgine Pharma UK Limited, which includes multiple performance obligations and various payment structures[46] - The company entered into a License and Supply Agreement with Norgine on January 13, 2025, receiving a one-time upfront payment of €28.5 million and a regulatory milestone payment of €0.5 million, with potential future payments totaling up to €225.6 million[79][80] Marketable Securities and Investments - The Company’s available-for-sale debt marketable securities as of September 30, 2025, had a fair value of $52.6 million[59] - The company incurred an unrealized loss on marketable securities of $10,000 for the three months ended June 30, 2025[25] Other Financial Metrics - The company recorded a change in fair value of warrant liability of $(12.8) million for the nine months ended September 30, 2025[25] - The fair value of the embedded derivative liability related to the Hercules Loan Agreement was estimated at $10 thousand as of September 30, 2025[60][62] - The Class C Warrant liability decreased from $13,755 thousand as of December 31, 2024, to $959 thousand as of September 30, 2025, reflecting a significant change in fair value[60][63]